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Abstract
Background: Symptom scales for aging women have clinically been used for years and the interest
in measuring health-related quality of life (HRQoL) has increased in recent years. The Menopause
Rating Scale (MRS) is a formally validated scale according to the requirements for quality of life
instruments. The aim of this paper is to review the current state of the instrument particularly
concerning versions of the scale in different languages.
MRS versions available: The translations were performed following international
methodological recommendations for the linguistic & cultural adaptation of HRQoL instruments.
The first translation was done from the German original scale into English (UK & USA). The English
version was used as the source language for the translations into French, Spanish, Swedish,
Mexican/Argentine, Brazilian, Turkish, and Indonesian languages (attached as additional PDF files).
Conclusion: The MRS scale is obviously a valuable tool for assessing health related quality of life
of women in the menopausal transition and is used worldwide. The currently available 9 language
versions have been translated following international standards for the linguistic and cultural
translation of quality of life scales. Assistance is offered to help interested parties in the translation
process.
Background
Symptoms such as impaired memory, lack of concentra-
tion, nervousness, depression, insomnia, periodic sweat-
ing or hot flushes, bone & joint complaints, and reduction
of muscle mass occur during menopausal transition.
Scales to measure menopausal or climacteric symptoms in
a standardized way have been developed and are widely
accepted. These scales, e.g. the Menopause Rating Scale
(MRS), measure health related quality of life [1,2].
The first widely accepted attempt to measure the severity
of menopausal complaints in women was the Kupperman
Index [3,4]. This instrument focuses primarily on sympto-
matic relief, assessed on the basis of the physician's sum-
mary of the severity of the climacteric complaints, i.e.
assisted by the index, rather than letting women assess
their perceived symptoms.
The MRS was developed and validated some years ago (5–
8) aiming at establishing an instrument to measure
HRQoL that can easily be completed by women. The aims
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of the MRS were (1) to enable comparisons of the symp-
toms of aging between groups of women under different
conditions, (2) to compare severity of symptoms over
time, and (3) to measure changes pre- and post-treatment
[7–9]. A review of reliability and validity was published
elsewhere [2]. Further details will not be discussed in this
paper.
Development and standardization were published else-
where [5]. In brief, the standardization of this scale was
performed on the basis of a representative sample of 500
German women aged 45–60 years in 1996. A factorial
analysis was applied to establish the raw scale of com-
plaints or symptoms. Statistical methods were used to
identify the dimensions of the scale. Finally, three dimen-
sions of symptoms/complaints were identified: a psycho-
logical, a somato-vegetative, and an urogenital factor that
explained 59 % of the total variance [5]. Reference values
for the severity of symptoms or complaints were calcu-
lated based on the population sample [5].
The scoring scheme is simple, i.e. the score increases point
by point with increasing severity of subjectively perceived
symptoms in each of the 11 items (severity 0 [no com-
plaints] 4 scoring points [very severe symptoms]). The
respondent provides her personal perception by checking
one of 5 possible boxes of "severity" for each of the items.
This can be seen in the questionnaires in the additional
files linked to this publication. The composite scores for
each of the dimensions (sub-scales) is based on adding up
the scores of the items of the respective dimensions. The
composite score (total score) is the sum of the dimension
scores. The three dimensions, their corresponding ques-
tions and the evaluation are detailed and summarized in
an attached file linked to this publication [see Additional
file 1].
The German original MRS scale was initially translated
and culturally adapted into English, showing cross-cul-
tural equivalence [10]. Sporadic information about trans-
lations into other than the two first languages required
attempts to inform the scientific community about
already existing international versions of the scale. In turn
we hope that we will be informed about language versions
that we are not aware of.
This should also help other international research groups
to have easy access to existing language versions, and to
prevent double translations.
MRS versions available
All translations were done by partners of our group and
following international methodological recommenda-
tions for the linguistic & cultural adaptation of HRQoL
measures [11,12], using the English version as source lan-
guage to ensure cross-cultural equivalence among coun-
tries. Six steps of the translation process were
recommended: Forward translations (at least two inde-
pendent translators), a consensus meeting with the coor-
dinator of the translation, a check by a bilingual expert to
evaluate the scientific correctness of the wording, a back-
ward translation, a consensus meeting among the transla-
tors with the coordinator, and finally a pretest with a few
subjects the test has been designed for (also called cogni-
tive debriefing).
In the translation process of the English version we real-
ized early that from the view of the North American trans-
lators further revision was essential. In a consensus
meeting, a wording was finally agreed upon that was com-
patible in both cultures and also in different social classes.
Thus, the English version is supposed to be compatible
with UK English and American English. Most of the other
existing versions were translated only for use in one spe-
cific country (France, Indonesia, Sweden). Two versions
exist for the Spanish language: For Spain itself and for
application in Mexico / Argentina (already applied in
these countries). The Portuguese version was developed in
Brazil and was not tested for use in Portugal. Recently we
got also the result of the linguistic/ cultural adaptation
into the Turkish language (as courtesy of Oslem C. Gur-
kan, College of Nursing, University of Mamara, Haydar-
papa / Ystanbul, Turkey, who coordinated the translation
process).
If the scale is to be applied in other countries with the
"same" language, at least a critical review of the transla-
tion will be necessary by a group experienced in the field
of cultural adaptation. In some cases, a new translation
may be required. This is a complex process that needs
expert experience, which can be provided by the authors
of this publication (LAJH).
Critical distance is particularly important if results of the
MRS are intended to be pooled between different popula-
tions or regions, and less important if a study is planned
as before-after-treatment-comparison in one country with
only one language. The latter applies only if the linguistic/
cultural adaptation process considered different social
classes and regions with slight language differences, which
is standard in experienced groups.
For access to the original scales in 9 different languages,
please see additional files linked to this publication:
• Additional file 1: Evaluation form of the MRS
• Additional file 2: German version of the MRS
• Additional file 3: English version of the MRSHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/28
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• Additional file 4: Swedish version of the MRS
• Additional file 5: French version of the MRS
• Additional file 6: Spanish version of the MRS
• Additional file 7: Mexican/Argentinean version of the
MRS
• Additional file 8: Turkish version of the MRS
• Additional file 9: Brazilian version of the MRS
• Additional file 10: Indonesian version of the MRS
It should be pointed out that individuals who are inter-
ested in using the MRS scale in their research can down-
load the appropriate language version and use it without
any formal permission. However, it would be important
to keep an overview who is using the scale and for what
reason. In return, all information on the scale that will
have become known in between will be made available.
Conclusions
The MRS scale is obviously a valuable tool for assessing
health related quality of life of women in the menopausal
transition and it is used worldwide. It is a standardized
scale meeting psychometric norms. The currently availa-
ble 9 language versions have been translated following
international standards for the linguistic and cultural
translation of quality of life scales. Assistance is offered to
help interested parties in the translation process.
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